ArticleCancer medicine2024

Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.

Wentao Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.